N umerous neuroprotective therapies have failed to improve the outcome of patients with acute ischemic stroke (AIS), making imperative the search for new alternatives. 1 Yet, dependence during clinical development on a single outcome measure may obscure potential treatment effects, making it advisable the inclusion of additional parameters sensitive to increase the statistical power of the study and reduce the necessary sample size of acute stroke trials. 2 An improved clinical end point selection may be informative and give important clues to justify additional clinical testing.
The assessment of early ischemic worsening (EIW) could be informative in the search of new neuroprotective strategies, given the strong association of this end point with poor long-term outcome. 3 Herein, we report a prespecified analysis of the URICO-ICTUS trial (Efficacy Study of Combined Treatment With Uric Acid and r-tPA in Acute Ischemic Stroke; online-only Data Supplement) assessing the effects of uric acid (UA) therapy to prevent EIW compared with placebo and the relevance of the collateral circulation.
Methods
The URICO-ICTUS trial was a phase IIb, multicenter, randomized, double-blind, placebo-controlled study that assessed the value of UA therapy in 411 patients with AIS treated with alteplase within 4.5 hours of clinical onset at 10 Spanish Stroke Centers between July 1, 2011, and April 30, 2013. Overall, 211 patients were treated with Background and Purpose-Identification of neuroprotective therapies in acute ischemic stroke is imperative. We report a predefined analysis of the URICO-ICTUS trial (Efficacy Study of Combined Treatment With Uric Acid and r-tPA in Acute Ischemic Stroke) assessing the efficacy of uric acid (UA) compared with placebo to prevent early ischemic worsening (EIW) and the relevance of collateral circulation. Methods-URICO-ICTUS was a double-blind, placebo-controlled, phase 2b trial where a total of 411 patients treated with alteplase within 4.5 hours of stroke onset were randomized (1:1) to receive UA 1000 mg (n=211) or placebo (n=200) before the end of alteplase infusion. EIW defined an increment ≥4 points in the National Institutes of Health Stroke Scale score within 72 hours of treatment in the absence of hemorrhage or recurrent stroke. Logistic regression models assessed the interaction between therapy and the collateral circulation in 112 patients who had a pretreatment computed tomographic angiography. The ethical boards of the participating centers gave approval of the study, and all participants (or their legal representatives) provided written informed consent. Good outcome at 90 days indicated a modified Rankin Scale score of 0 to 1 or a modified Rankin Scale score of 0 to 2 in patients with a premorbid modified Rankin Scale score of 2.
Results-EIW
4 EIW defined an increment of at least 4 points in the National Institutes of Health Stroke Scale score within the first 72 hours of stroke, not attributable to hemorrhagic complications or recurrent stroke. A blinded central committee reviewed the imaging data of the study and a contract research organization audited all events registered as EIW in an electronic case record form. A subgroup of 112 patients admitted into Comprehensive Stroke Centers (56 treated with UA and 56 treated with placebo) had full assessment of the collateral circulation using advanced brain imaging (Methods in the online-only Data Supplement). Collaterals were assessed on brain computed tomographic angiography according to a validated grading system that ranged from 0 to 3 (0, absent collateral supply; 1, collateral supply filling <50%; 2, collateral supply filling >50% but <100% of the occluded arterial territory; and 3, 100% collateral supply). 5 Analyses used SPSS Version 19.0 and included the χ 2 or Fisher exact test to compare categorical variables, the t test for continuous Gaussian-distributed variables, and the Mann-Whitney for ordinal and non-Gaussian continuous data. Logistic regression models assessed the interaction between therapy and the collateral circulation. The level of significance was 0.05 level (2-sided).
Results
Age, baseline National Institutes of Health Stroke Scale score, hypertension, and smoking status were associated with EIW, and atherothrombotic stroke, female sex, pretreatment hyperglycemia, and history of atrial fibrillation showed statistical trends (Table I in the online-only Data Supplement).
EIW occurred in 2 of 149 (1%) patients with good outcome and in 23 of 262 (9%) patients with poor outcome (χ 2 ; P=0.002). Other variables associated with outcome at 90 days were age, premorbid modified Rankin Scale score, National Institutes of Health Stroke Scale score at randomization, pretreatment serum glucose, and time from stroke onset to UA therapy (Table II in (Tables III and IV in the online-only Data Supplement). In this cohort, several advanced imaging traits predicted a higher incidence of EIW, including the collateral score, the amount of nonviable tissue, and the amount of hypoperfused tissue, respectively (Table) . Nonetheless, only the collateral score showed a significant interaction with the efficacy of UA therapy to prevent EIW (Table and Figure) .
Discussion
This tertiary analysis of the URICO-ICTUS trial showed that UA therapy reduced significantly the incidence of EIW compared with placebo in patients treated with alteplase within 4.5 hours of AIS onset. A significant interaction between the treatment effects and the collateral score highlighted the relevance of adequate access of neuroprotectant drugs to its molecular targets. The association found between EIW and poor longterm outcome also supported the inclusion of this end point as a sensitive surrogate marker of clinical efficacy in future acute stroke trials.
EIW may result from numerous biochemical and hemodynamic mechanisms [6] [7] [8] [9] [10] that may converge to produce damaging 
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concentrations of free radicals during brain ischemia. 1, 11 UA is the main endogenous antioxidant in human plasma, 12 but its concentration decreases after AIS in parallel with the fate of the brain ischemic tissue and the long-term functional outcome. 13 UA scavenges hydroxyl radicals, hydrogen peroxide, and peroxynitrite and prevents lipid peroxidation, 13 and these effects mainly take place within the walls of brain vessels.
14 In experimental stroke models, UA therapy reduces brain damage and acts synergistically with alteplase in thromboembolic models. 15 In conclusion, although the URICO-ICTUS trial was not able to demonstrate the superiority of UA therapy over placebo for increasing the rate of good clinical outcome at 90 days, this exploratory analysis highlights the association of EIW with long-term outcome and the efficacy of UA therapy to reduce the incidence of EIW in patients with AIS receiving thrombolytic therapy. Collectively, these results justify the funding of a larger confirmatory clinical trial assessing the definitive value of UA therapy to improve the outcome of patients with AIS.
Supplemental Material
Tittle: Uric acid therapy prevents early ischemic stroke progression: a tertiary analysis of the URICO-ICTUS trial. 
Supplementary Methods
Brain Imaging
A simple CT scan was the only brain imaging technique required in the URICO-ICTUS trial but an advanced brain imaging battery was planned in selected centres. The advanced brain imaging protocol included the use of CT-perfusion (CTP), CT-angiography (CTA) and/or Digital Subtraction Angiography (DSA), performed before randomization to the experimental therapy. The Advanced Neuroimaging Cohort included a group of 112 patients who had CTP and CTA showing acute perfusion deficits in the carotid territory at baseline. Of those, 56 patients were treated with uric acid and 56 patients were treated with placebo. CTP was performed using a SIEMENS Somatom Definition Flash 128-section dual-source multidetector scanner (Siemens Healthcare, Erlangen, Germany), with a 98 mm z-coverage and 26 time points acquired each 1.5 s (total acquisition time, 39 s). Perfusion images were reconstructed as 2-mm slices and CTP maps were calculated by commercial software MIStar (Apollo Medical Imaging Technology, Melbourne, Australia) using singular value decomposition (SVD) with a delay correction. The software generated perfusion maps, which included cerebral blood flow (CBF), cerebral blood volume (CBV), delay time (DT), mean transit time (MTT), mean of all slices (Mean) and a penumbra map that included nonviable tissue (NVT) and tissue-at-risk (TAR). An absolute threshold of 2s was selected on the DT map to obtain the volume of hypoperfusion. Inside this area, a relative threshold of 30% of the mean CBF value in the unaffected/contralateral hemisphere was used to obtain NVT volumes. TAR was obtained by subtracting the NVT volume to the total hypoperfused tissue volume. The Alberta Stroke Program Early CT Score (ASPECTS) estimated on brain CT scan the extent of the infarction at the onset of alteplase therapy.
